- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
GnRH agonists' safety profile under FDA review for diabetes, CVD risks
FDA notified providers and patients that they are continuing to review available data suggesting an increase in the risk of diabetes, heart attack, stroke, and sudden death in men treated with gonadotropin-releasing hormone agonists as androgen deprivation therapy for prostate cancer.
Key Points
On May 3, 2010, FDA notified providers and patients that they are continuing to review available data suggesting an increase in the risk of diabetes, heart attack, stroke, and sudden death in men treated with gonadotropin-releasing hormone (GnRH) agonists as androgen deprivation therapy (ADT) for prostate cancer.
GnRH agonists including leuprolide acetate, sold under the brand names Lupron (Abbott), Viadur (Bayer), and Eligard (Sanofi-aventis), goserelin acetate (Zoladex, AstraZeneca), triptorelin pamoate (Trelstar, Watson), histrelin acetate (Vantas, Endo Pharmaceuticals), and nafarelin acetate (Synarel, Pfizer) suppress the production of testosterone, a hormone that is involved in the growth of prostate cancer. Consequently, such agents shrink or slow the growth of prostate tumors.
According to FDA, a number of administrative claims- or registries-based observational studies have "reported small, but statistically significant increased risks of diabetes and/or cardiovascular events in patients receiving GnRH agonists." Specifically, the agency references 6 studies evaluating patients undergoing ADT to treat prostate cancer versus patients not undergoing this treatment. However, the agency cautions that "these studies have design limitations that make it difficult to confirm a cause and effect relationship."
Patients are being urged not to stop their treatment with GnRH agonists unless told to do so by their provider.
SOURCES
FDA. FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases. May 3, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209842.htm. Accessed May 10, 2010.
Levine GN, D'Amico AV, Berger P, et al; on behalf of the American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association. Circulation. 2010;121:833–840.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
